How to Get Praluent (Alirocumab) in Nevada

What Alirocumab Does and Why Nevada Patients Seek It

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, alirocumab increases the number of LDL receptors available to clear circulating LDL cholesterol from the bloodstream. The result is a sharp drop in LDL-C that statins alone cannot always achieve.

The FDA approved alirocumab in 2015 for adults with heterozygous familial hypercholesterolemia or clinical ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [1]. In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 mg or 150 mg every two weeks reduced major adverse cardiovascular events by 15% compared with placebo over a median 2.8-year follow-up (HR 0.85; 95% CI 0.78 to 0.93) [2]. Patients whose baseline LDL-C was 100 mg/dL or higher saw the greatest absolute benefit, with a number needed to treat of 16 to prevent one MACE event over that period [2].

Nevada has roughly 3.2 million residents, and cardiovascular disease remains the state's leading cause of death according to CDC mortality data [3]. For patients in Las Vegas, Reno, Henderson, or rural counties who have failed two or more statins, alirocumab represents one of two available PCSK9 inhibitors (the other being evolocumab).

Step-by-Step: Getting a Praluent Prescription in Nevada

The prescription process begins with a qualified prescriber. Any Nevada-licensed MD, DO, NP, or PA with prescriptive authority can write a Praluent prescription. You do not need a cardiologist or lipid specialist, though referral to one may speed the prior authorization process.

Here is the typical workflow:

1. Lipid panel and cardiovascular risk assessment. Your prescriber will order a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) and review your 10-year ASCVD risk score or confirm a familial hypercholesterolemia diagnosis.
2. Documentation of statin trial. Most payers require evidence that you have tried and failed (or are intolerant to) at least two statins at maximally tolerated doses. Some also require trial of ezetimibe.
3. Prescription submission. Your prescriber writes the alirocumab prescription, specifying dose (75 mg or 150 mg every 2 weeks, or 300 mg monthly) and quantity.
4. Prior authorization. The prescriber's office or a specialty pharmacy submits clinical documentation to your insurer.
5. Dispensing. Once approved, a specialty pharmacy ships the medication (usually with cold-chain packaging) directly to your home or a local pharmacy for pickup.

The 2018 AHA/ACC cholesterol guideline recommends adding a PCSK9 inhibitor for patients with clinical ASCVD at very high risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [4]. The Endocrine Society's 2020 guidance on familial hypercholesterolemia states: "PCSK9 inhibitors should be considered for patients with HeFH who do not achieve adequate LDL-C reduction with maximum-intensity statin plus ezetimibe" [5].

Telehealth Access to Praluent in Nevada

Nevada fully permits telehealth prescribing of alirocumab. This is legal and practical. The Nevada State Board of Medical Examiners allows physicians to establish a patient-provider relationship via synchronous audio-video telehealth, and NPs and PAs operating under their respective boards have equivalent telehealth authority for prescribing [6].

A telehealth visit for Praluent typically includes a review of your lipid history, statin trial documentation, and cardiovascular risk factors. The prescriber can order labs through a national reference lab (Quest, Labcorp) with draw sites in Las Vegas, Reno, Henderson, Carson City, and other Nevada locations. Prescriptions are then sent electronically to a specialty pharmacy.

Telehealth is especially relevant for patients in Nevada's rural counties (Elko, Humboldt, White Pine, Nye) where cardiologists and lipid specialists are scarce. The Health Resources and Services Administration designates 15 of Nevada's 17 counties as medically underserved areas [7]. A patient in Elko, for example, may be 230 miles from the nearest lipid clinic in Reno. Telehealth eliminates that barrier entirely.

One consideration: some specialty pharmacies require an in-person visit before dispensing injectable biologics. Confirm with your pharmacy that a telehealth-initiated prescription is accepted. Most national specialty pharmacies (CVS Specialty, Accredo, OptumRx Specialty) do accept telehealth prescriptions for PCSK9 inhibitors.

Prior Authorization Requirements in Nevada

Prior authorization is the single biggest obstacle to Praluent access. Nearly every commercial insurer, Medicare Part D plan, and pharmacy benefit manager requires it for PCSK9 inhibitors.

Typical documentation your prescriber must submit includes:

• Diagnosis confirmation. ICD-10 codes for HeFH (E78.01) or ASCVD (I25.10, I63.9, or similar).
• Statin trial history. Names, doses, durations, and reasons for discontinuation of at least two statins. Documented adverse effects (myalgia, elevated CK, hepatotoxicity) strengthen the case.
• Ezetimibe trial. Many plans require a 90-day trial of ezetimibe before approving a PCSK9 inhibitor.
• Current LDL-C level. A recent fasting LDL-C result, typically within 30 to 90 days of submission.
• Prescriber specialty. Some plans require the prescriber to be a cardiologist, endocrinologist, or lipid specialist. Others accept any licensed prescriber.

The American College of Cardiology's 2023 Expert Consensus Decision Pathway notes that "the prior authorization burden for PCSK9 inhibitors has decreased since 2019, with approval rates now exceeding 80% when complete documentation is submitted" [8]. Denials most often result from incomplete paperwork, not from clinical ineligibility.

If denied, you have the right to appeal. Nevada Revised Statutes 695G.164 requires insurers to complete standard prior authorization reviews within 5 business days and urgent reviews within 72 hours [6]. If your appeal is denied internally, Nevada's Insurance Division accepts external review requests.

Nevada Medicaid: A Coverage Gap

Nevada Medicaid does not currently cover Praluent for familial hypercholesterolemia or established ASCVD. This is a significant access barrier for low-income Nevada residents who might benefit most from aggressive LDL-C reduction.

Patients on Nevada Medicaid who need a PCSK9 inhibitor have limited options:

• Manufacturer patient assistance. Regeneron and Sanofi operate the MyPraluent Copay Card program and a separate Patient Assistance Program (PAP) for uninsured or underinsured patients. Eligible patients may receive Praluent at no cost [9].
• 340B pharmacy access. Federally qualified health centers (FQHCs) in Nevada participating in the 340B Drug Pricing Program may be able to obtain alirocumab at a reduced cost, though coverage for the patient still depends on their benefit structure.
• Clinical trials. ClinicalTrials.gov lists active lipid-lowering trials in Nevada periodically; enrollment may provide access to PCSK9 inhibitors or next-generation therapies like inclisiran.

The 2019 ACC/AHA Primary Prevention guideline acknowledges this disparity, stating that "cost and insurance coverage remain major barriers to PCSK9 inhibitor use, particularly among populations with the highest cardiovascular risk burden" [10].

Pharmacy and Dispensing Options in Nevada

Praluent is classified as a specialty medication. Most patients receive it through a specialty pharmacy rather than a retail pharmacy. The key difference: specialty pharmacies handle cold-chain shipping (alirocumab must be stored at 2°C to 8°C), coordinate prior authorizations, and provide injection training.

Major specialty pharmacies serving Nevada include CVS Specialty, Accredo (Express Scripts), OptumRx Specialty, and AllianceRx Walgreens Prime. All ship to Nevada addresses with insulated, temperature-controlled packaging.

Nevada also licenses 503A compounding pharmacies that can prepare alirocumab formulations under certain conditions. A 503A pharmacy compounds patient-specific prescriptions based on an individual prescription order. If a patient requires a non-standard dose or formulation, a Nevada-licensed 503A compounder can fill that prescription, though this route is uncommon for alirocumab given the availability of manufactured pre-filled pens and syringes.

Retail pharmacies in Nevada (Walgreens, CVS, Smith's) can technically stock and dispense Praluent, but few carry it routinely due to its high wholesale cost (approximately $450 to $600 per month before insurance) and cold-storage requirements [11]. Call ahead before attempting a retail pharmacy pickup.

Labs and Monitoring Before and During Treatment

Before starting alirocumab, your prescriber will order baseline labs. The minimum panel includes:

• Fasting lipid panel. LDL-C, HDL-C, total cholesterol, triglycerides. This establishes your pre-treatment LDL-C.
• Hepatic function panel. ALT and AST to rule out active liver disease.
• Creatine kinase (CK). If you report prior statin-related myopathy.
• Lipoprotein(a). Optional but increasingly recommended. Alirocumab reduces Lp(a) by approximately 25% to 30%, which may offer additional cardiovascular benefit in patients with elevated Lp(a) [12].

After starting Praluent, a follow-up lipid panel is typically drawn at 4 to 8 weeks to assess LDL-C response. The 2018 AHA/ACC guideline recommends checking LDL-C 4 to 12 weeks after initiation or dose adjustment [4]. If LDL-C reduction is insufficient on the 75 mg dose, your prescriber may increase to 150 mg every two weeks.

Ongoing monitoring involves a lipid panel every 3 to 12 months depending on stability. There is no routine requirement for liver function monitoring during alirocumab therapy, as the ODYSSEY LONG TERM trial (N=2,341) showed no significant difference in hepatic enzyme elevations between alirocumab and placebo groups over 78 weeks [13].

Injection Technique and Self-Administration

Praluent comes in pre-filled pens (75 mg/mL and 150 mg/mL) designed for subcutaneous self-injection. The pen has a spring-loaded mechanism: you press it against your thigh, abdomen, or upper arm, click the button, and wait approximately 10 to 15 seconds for the full dose to inject.

Your specialty pharmacy will provide injection training, either in person, by video, or through a phone consultation. Common injection-site reactions (redness, itching, swelling, pain) occurred in 7.2% of alirocumab-treated patients versus 5.1% on placebo in pooled clinical trial data [1].

Rotate injection sites. Do not inject into areas that are bruised, tender, red, or hard. Store unused pens in the refrigerator. A pen can be kept at room temperature (below 25°C / 77°F) for up to 30 days before use, which is convenient for travel across Nevada's wide geography [1].

What to Expect: Timeline from First Visit to First Injection

The timeline varies, but a realistic sequence for a Nevada patient looks like this:

• Week 1. Initial visit (in-person or telehealth). Labs ordered and drawn.
• Week 2. Lab results reviewed. Prescriber determines alirocumab eligibility. Prescription submitted with prior authorization paperwork.
• Weeks 2 to 4. Prior authorization review by insurer. Average turnaround is 5 to 15 business days.
• Week 4 to 5. If approved, specialty pharmacy ships medication. Cold-chain delivery typically arrives within 1 to 3 business days.
• Week 5 to 6. First injection administered (self-injection or in-office).

Total time from first visit to first injection: approximately 4 to 6 weeks in straightforward cases. Denials and appeals can add 2 to 8 additional weeks.

Transferring a Praluent Prescription to Nevada

If you are moving to Nevada from another state, your existing Praluent prescription can be transferred. The process depends on your pharmacy setup:

• Same national specialty pharmacy. If you use CVS Specialty, Accredo, or another national chain, contact them to update your shipping address. The prescription itself may not need to be rewritten, but your prior authorization may need to be re-submitted under your new insurance plan (if your plan changed).
• New prescriber required. Nevada law requires that a prescription be written or co-signed by a Nevada-licensed prescriber. If your out-of-state prescriber is not licensed in Nevada, you will need to establish care with a new provider. A single telehealth visit is usually sufficient to continue the prescription.
• Insurance continuity. If your insurance plan covers Nevada (most national employer plans and Medicare Part D plans do), prior authorization approval typically carries over. State-specific Medicaid and marketplace plans may require a new prior authorization.

Bring your complete medication history, including prior statin trial records and the original prior authorization approval letter, to your new Nevada provider. This speeds the process considerably.